



9p/1612

PATENT BOX  
Attorney Docket No. AR138-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gregory S. HAMILTON et al.

Group Art Unit: 1612

Serial No. 09/204,238

Examiner: Celia Chang

Filed: December 3, 1998

RECEIVED

JAN 03 2000

TECH CENTER 1600/2900

For: **MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING  
COMPOUNDS SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES  
THEREOF**

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal letter; and
- 2) Letter to the Examiner.

If extensions of time under 37 CFR § 1.136 other than those provided herewith are required to allow consideration of papers accompanying this Petition, then such extensions of time are hereby petitioned. The Commissioner is specifically authorized to charge fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES**

Date: Dec. 30, 1999


By: Todd L. Juneau

**NATH & ASSOCIATES**

1030 Fifteenth Street N.W.  
Sixth Floor  
Washington, D.C. 20005-1503  
TEL: (202) 775-8383  
FAX: (202) 775-8396

GMN:TLJ:JBG:\roadmap.tl

Gary M. Nath  
Reg. No. 26,965  
Todd L. Juneau  
Reg. No. 40,669



#14

BOX PATENT  
Attorney Docket No. AR138-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gregory S. HAMILTON et al.

Examiner: Celia Chang

Serial No: 09/204,238

Group: 1612

Filed: December 3, 1998

For: **MULTIPLE HETEROATOM CONTAINING HETEROCYCLIC RING  
COMPOUNDS SUBSTITUTED WITH CARBOXYLIC ACIDS AND ISOSTERES  
THEREOF**

**LETTER TO THE EXAMINER**  
**REGARDING INFORMATION DISCLOSURE STATEMENTS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants herein provide a brief description of material described in each reference cited in the Information Disclosure Statement, filed July 15, 1999; Supplemental Information Disclosure Statement, filed July 14, 1999; Third Supplemental Information Disclosure Statement filed October 8, 1999; and Fourth Supplemental Information Disclosure Statement filed October 21, 1999. A brief description of the material described in each reference cited in the Second Supplemental Information Disclosure Statement, filed October 8, 1999, was provided therewith. This outline is provided for the convenience of the Examiner and to advance the prosecution of the present application before the United States Patent and Trademark Office.

The Examiner's attention is drawn to the following IDS references containing biological information that the Examiner may find relevant for reviewing the subject matter of the present

invention. The identification letters shown below (**AD**, **AE**, etc.) refer to the reference line numbers cited in the respective Information Disclosure Statements.

Nerves- growth of; regeneration; degeneration:

Information Disclosure Statement:

**AB**.

First Supplemental Information Disclosure Statement:

**AA**, **AB**, **AE**, **AH**, **AO**, **BD**, **BF**, **BG**, **BH**, and **BJ**.

Third Supplemental Information Disclosure Statement:

**AB**, **AC**, **AD**, **AE**, **AF**, **AG**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AO**, **AP**, **AQ**,  
**AR**, **AS**, **AT**, **AU**, **AV**, **AW**, **BB**, **BN**, **BO**, **BR**, **BY**, **CL**, **DC**, **DG**,  
and **EF**.

Fourth Supplemental Information Disclosure Statement:

**AA**, **AB**, **AC**, **AD**, **AE**, **AF**, **AG**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AQ**, **AW**,  
and **BF**.

Alzheimer's disease:

Information Disclosure Statement:

**AB**.

First Supplemental Information Disclosure Statement:

**AA**, **AB**, **AE**, **AH**, **AN**, **AO**, **BB**, **BD**, **BF**, **BG**, and **BH**.

Third Supplemental Information Disclosure Statement:

**AB**, **AC**, **AE**, **AF**, **AG**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AN**, **AO**, **AP**, **AQ**,  
**AR**, **AS**, **AT**, **AU**, **AV**, **AW**, **BB**, **BN**, **BO**, **BR**, **BY**, **CL**, **DC**, **DG**,  
and **EF**.

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AP, AQ, AW, AX, BE, and BF.**

Parkinson's disease:

Information Disclosure Statement:

**AB.**

First Supplemental Information Disclosure Statement:

**AA, AB, AE, AH, AO, BD, and BG.**

Third Supplemental Information Disclosure Statement:

**AB, AC, AE, AF, AG, AI, AJ, AK, AL, AO, AP, AQ, AR, AS, AT, AU, AV, AW, BN, BO, BY, DC, DG, and EE.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AW, and BF.**

Amyotrophic lateral sclerosis:

Information Disclosure Statement:

**AB and AC.**

First Supplemental Information Disclosure Statement:

**AA, AB, AE, AG, AH, AM, AN, BE, BG, and BI.**

Third Supplemental Information Disclosure Statement:

**AB, AC, AE, AF, AG, AI, AJ, AK, AL, AM, AO, AP, AQ, AR, AS, AW, BJ, BL, BP, and BY.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AH, AI, AJ, AK, AL, AN, AX, and AW.**

Cerebral ischemia:

First Supplemental Information Disclosure Statement:

**AB, AC, BB, and BK.**

Third Supplemental Information Disclosure Statement:

**AB, AC, AG, AI, AJ, AK, AN, AO, AP, AQ, AR, BN, BO, BR,  
CI, and EA.**

Fourth Supplemental Information Disclosure Statement:

**AL and AW.**

Degenerative disorders of nervous system; CNS disorders:

Information Disclosure Statement:

**AB.**

First Supplemental Information Disclosure Statement:

**AA, AE, AH, AL, AO, BB, BD, BF, and BH.**

Third Supplemental Information Disclosure Statement:

**AE, AF, AL, AP, AS, BI, BN, BR, CM, DC, EB, EE, EF, and  
EG.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AM, AO, BA,  
BB, BC, and BD.**

Memory or Dementia:

First Supplemental Information Disclosure Statement:

**BB, BC, BF, and BH.**

Third Supplemental Information Disclosure Statement:

**AE, AF, AP, AQ, AT, AU, and BY.**

Fourth Supplemental Information Disclosure Statement:

**AO, AP, AQ, BC, BE, and BH.**

Eye or vision, or similar disorders:

Information Disclosure Statement:

**AC.**

First Supplemental Information Disclosure Statement:

**AA, AB, AD, AE, AG, AH, AI, AJ, AM, AN, AO, BE, BI, BJ,**  
and **BK.**

Third Supplemental Information Disclosure Statement:

**AA, AM, AN, AP, AQ, BJ, BL, BP, BAC, CG, and CK.**

Fourth Supplemental Information Disclosure Statement:

**AN, AT, AV, and AX.**

Hair Growth or Alopecia:

Information Disclosure Statement:

**AA.**

First Supplemental Information Disclosure Statement:

**AC, AD and BA.**

Third Supplemental Information Disclosure Statement:

**AD, AG, AH, AM, AX, BA, BB, BC, BE, BG, BH, BQ, BS, BT,**  
**BU, BW, BX, BZ, DB, DD, DE, and EH.**

Fourth Supplemental Information Disclosure Statement:

**AX.**

The following references disclose chemical structures that the Examiner may find relevant for reviewing the subject matter of the present invention.

Information Disclosure Statement:

**AA, AC, AD, AE, and AF.**

First Supplemental Information Disclosure Statement:

**AA, AG, AM, BE, BI, CA and CB.**

Third Supplemental Information Disclosure Statement:

**AA, AB, AD, AF, AI, AL, AR, AY, AZ, BD, BF, BI, BJ, BK,  
BL, BM, BV, BAA, BAB, CA, CB, CC, CD, CE, CF, CH, and DF.**

Fourth Supplemental Information Disclosure Statement:


**AB, AG, AH, AK, AL, AM, AN, AR, AS, AU, BG, and BI.**

Applicants have taken great care to ensure that the claims of the present invention are patentable over all cited references, but welcome and appreciate the Examiner's consideration of the same.

Please contact the undersigned attorney by telephone should there be any questions or comments.

Respectfully submitted,  
**NATH & ASSOCIATES**

Date: Dec 30, 1999

  
\_\_\_\_\_  
Gary M. Nath  
Reg. No. 26,965  
Todd L. Juneau  
Reg. No. 40,669

**NATH & ASSOCIATES**

1030 Fifteenth Street, N.W.  
Sixth Floor  
Washington, D.C. 20005  
(202) 775-8383  
GMN:TLJ:JBG:\roadmap